Medical University to use X-MAN Cell Lines in Japan 

Horizon Discovery™ a leading provider of research tools to support translational genomics and the development of personalised medicines, has entered into a limited use academic license agreement with a Japanese medical university covering 250 of Horizon’s X-MAN™ genetically defined, isogenic cell lines.

Kam Dhaliwal, VP Sales, Horizon Discovery, commented: “This is a very significant deal for Horizon Discovery, covering a large number of cell lines and representing a large investment by the university. We are delighted that our distribution partnership in Japan with Summit Pharmaceuticals International (SPI) is proving so productive.  Summit has proven to be extremely effective in opening the Japanese market for Horizon and we anticipate further adoption of our products and services in Japan in the future.”

The director of the Translational Research Centre at the university commented: “Horizon’s X-MAN cell lines offer a unique and valuable resource for the study of specific, disease-related mutations. We are look forward to applying the X-MAN technology in our research projects.”